Dipali Nemade, MD
Epilepsy · Orlando, FLNPI 1679008387
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 83.7% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $20,454, more than ten times the $30 reported in 2020.
Across 305 payments — averaging $125.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$32K
- Neuropace, Inc.$1K
- Medtronic$1K
- AbbVie$751
- Neurelis, Inc.$382
- Acadia Pharmaceuticals Inc$323
- plus $2K from 33 others
What the payments were for
- Consulting fees$7,35019%
- Speaking & faculty fees$19,90052%
- Travel & lodging$3,75010%
- Food & beverage$7,23719%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 113 | $32,005 |
| Neuropace, Inc. | 8 | $1,310 |
| Medtronic | 7 | $1,161 |
| AbbVie | 53 | $751 |
| Neurelis, Inc. | 11 | $382 |
| Acadia Pharmaceuticals Inc | 16 | $323 |
| SK Life Science, Inc. | 8 | $319 |
| Catalyst Pharmaceuticals, Inc. | 12 | $285 |
| Biogen | 8 | $173 |
| Jazz Pharmaceuticals Inc. | 7 | $169 |
| Pfizer | 7 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $119 |
| AstraZeneca | 4 | $107 |
| Teva Pharmaceuticals USA, Inc. | 5 | $93 |
| Lilly USA, LLC | 5 | $88 |
| Amgen | 3 | $81 |
| Genentech USA, Inc. | 3 | $72 |
| Grifols USA, LLC | 1 | $62 |
| Cala Health, Inc. | 2 | $60 |
| MDD US Operations, LLC | 3 | $51 |
| Livanova USA, Inc. | 2 | $47 |
| Eisai Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| CSL Behring | 1 | $28 |
| Lundbeck LLC | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Sanofi | 1 | $24 |
| Aucta Pharmaceuticals, Inc. | 2 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $22 |
| Insightec,inc | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| ITF Therapeutics LLC | 1 | $19 |
| TG Therapeutics, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,253 in reported general payments places this provider in the 80th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 72 | $130,503 |
| XcopriCenobamate | 19 | $39,027 |
| QuliptaAtogepant | 24 | $26,839 |
| Lamotrigine ErLamotrigine | 17 | $8,991 |
| Levetiracetam | 123 | $4,364 |
| Lacosamide | 19 | $1,204 |
| Lamotrigine | 52 | $1,043 |
| Oxcarbazepine | 17 | $885 |
| Levetiracetam ErLevetiracetam | 22 | $839 |
| Clobazam | 22 | $832 |
| Clonazepam | 12 | $580 |
| Phenytoin Sodium Extended | 13 | $348 |
| Gabapentin | 16 | $293 |
| Topiramate | 13 | $45 |
| Alprazolam | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $32,005 | $130,50372 claims |
| SK Life Science, Inc.Xcopri | $319 | $39,02719 claims |
| AbbVieQulipta | $751 | $26,83924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 23 epilepsy providers in Florida.
Other epilepsy in Orlando
- Jaivir RathoreOrlando$38K
- Bruno MatonOrlando$2K
- Brian CostellBoca Raton$469K
- Andrew LermanMiami$249K
- Alberto Pinzon ArdilaMiami$144K
- Mohamed NasserWeston$28K
- William TatumJacksonville$28K
- Brin FreundJacksonville$18K
- Miguel Melo-BicchiMiami$15K
- Claudio OsorioTampa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.